Department of Urology, Dankook University College of Medicine, Cheonan, Korea.
Int Neurourol J. 2012 Dec;16(4):187-90. doi: 10.5213/inj.2012.16.4.187. Epub 2012 Dec 31.
To evaluate whether intravesical protrusion of the prostate (IPP) is related to the treatment effect of alpha-1 receptor antagonist in patients with lower urinary tract symptoms (LUTS)/benign prostatic hyperplasia (BPH) with a prostate size of less than 40 g.
A total of 77 BPH patients over 50 years of age treated with alfuzosin (alpha blocker) were enrolled prospectively. The study included only patients with BPH of 40 g or less. The patients were classified into two groups depending on the presence of IPP at baseline: the IPP group (41 patients) and the non-IPP group (36 patients). Prostate volume, prostate-specific antigen (PSA), International Prostate Symptom Score and quality of life (IPSS/QoL), maximum flow rate (Qmax), and postvoid residual (PVR) volume were compared between the groups. The clinical significance of IPP was evaluated after the patients had been taking alfuzosin for 8 weeks.
PSA and IPSS (total and voiding subscore) showed significant correlations with IPP (P<0.05). Comparison of parameters before and after 8 weeks showed that alfuzosin improved the total IPSS and all subscores (P<0.001), QoL (P<0.001), Qmax (P<0.001), and PVR (P=0.030) in the non-IPP group.
Alfuzosin may be less effective in improving symptom scores, PVR, and Qmax in the treatment of LUTS/BPH in the presence of IPP.
评估前列腺内突（IPP）是否与前列腺体积小于 40g 的下尿路症状（LUTS）/良性前列腺增生（BPH）患者接受α-1 受体拮抗剂治疗的效果相关。
前瞻性纳入 77 例接受阿夫唑嗪（α受体阻滞剂）治疗的 50 岁以上 BPH 患者。该研究仅纳入 BPH 患者 40g 或以下的患者。根据基线时是否存在 IPP 将患者分为两组：IPP 组（41 例）和非 IPP 组（36 例）。比较两组间前列腺体积、前列腺特异性抗原（PSA）、国际前列腺症状评分和生活质量（IPSS/QoL）、最大尿流率（Qmax）和残余尿量（PVR）。评估患者服用阿夫唑嗪 8 周后 IPP 的临床意义。
PSA 和 IPSS（总分和排尿分项）与 IPP 呈显著相关（P<0.05）。8 周前后参数比较显示，阿夫唑嗪改善了非 IPP 组的总 IPSS 及所有分项（P<0.001）、生活质量（P<0.001）、Qmax（P<0.001）和 PVR（P=0.030）。
在存在 IPP 的情况下，阿夫唑嗪治疗 LUTS/BPH 时可能对改善症状评分、PVR 和 Qmax 的效果较差。
